Q2FY23 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.
Tatva Chintan Pharma Chem announced Q2FY23 results: Consolidated: YoY Q2FY23 vs Q2FY22: Revenue from Operations for the quarter was Rs. 901 million, which declined by 27% EBITDA for the quarter was Rs. 112 million, which declined by 68% EBIDTA Margin for the quarter was at 12% Net Profit for the quarter was Rs. 71 million, which declined by 78% Net Profit Margin for the quarter was at 8% Basic and Diluted EPS for the quarter was Rs. 3.21 per share YoY H1FY23 vs H1FY22: Revenue from Operations for the half year was Rs. 1,785 million, which declined by 23% EBITDA for the half year was Rs. 264 million, which declined by 57% EBIDTA Margin for the half year was at 15% Net Profit for the half year was Rs. 169 million, which declined by 70% Net Profit Margin for the half year was at 9% Basic and Diluted EPS for the half year was Rs. 7.63 per share Commenting on Q2FY23 Results, Mr. Chintan Shah, Managing Director, said, EBITDA during this quarter was Rs. 112 million, a decline of 68% YoY and 27% QoQ. EBIDTA includes a forex loss of Rs. 31.85 million, so the actual operational EBIDTA during the quarter is Rs. 143.62 million which translates into an EBIDTA margin of 16%. Forex loss is mainly because of the MTM of the forward contract due to the depreciating rupee. PAT was Rs. 71 million, a decline of 78% YoY and 27% QoQ. Compared to the QoQ basis, the profitability has dropped due to an increase in costs such as power & fuel, packing and employee costs during this quarter Result PDF04-11-2022